Lupin’s Pegfilgrastim Biosimilar Accepted By US FDA
Neulasta Rival Faces A Crowded Market With Four Approved Competitors
Lupin’s first US biosimilar application, for a rival to Neulasta, has been accepted for filing by the FDA. If approved, the product would join an already crowded market for pegfilgrastim in the US.
